<DOC>
	<DOCNO>NCT00915785</DOCNO>
	<brief_summary>The purpose study assess hematological cytogenetic response 5 azacytidine patient 55 year age MDS/AML due chromosome 7 abnormality assess hematological cytogenetic response rate patient relapse AML chromosome 7 abnormality .</brief_summary>
	<brief_title>Azacytidine Treatment Myelodysplastic Syndromes/Acute Myeloid Leukemia ( MDS/AML ) With High Risk ( Chromosome 7 Complex ) Cytogenetic Abnormalities</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Chromosome Aberrations</mesh_term>
	<mesh_term>Chromosome Disorders</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Abnormalities chromosome 7 , include monosomy 7 either alone part complex clone . Be &gt; 55 year age ; young first subsequent relapse patient less &lt; 55 year chromosome 7 abnormality alone part complex clone . Have International Prognostic Scoring System ( IPSS ) score INT 1.5 diagnosis RAEB RAEBT per FrenchAmericanBritish ( FAB ) classification criterion diagnosis Myelodysplastic CMMoL per modify FAB criterion meet follow : Monocytosis peripheral blood &gt; 1x109/L ; Dysplasia one myeloid cell line ; 10 % 29 % blast BM ; White blood cell ( WBC ) &lt; 13,000 x109/L ; Have life expectancy least 3 month ; Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status Grade 02 . Have serum bilirubin level least 1.5 x upper limit normal range laboratory ( ULN ) . Higher level acceptable attribute : active hemolysis ( indicated positive direct Coombs ' testing ) ; decrease absent haptoglobin level ; elevate indirect bilirubin and/or lactate dehydrogenase [ LDH ] ) ; ineffective erythropoiesis ( indicated bone marrow finding ) . Have serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamicpyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) level least 2 x ULN . Have serum creatinine level least 1.5 x ULN . Women childbearing potential may participate , provide meet following condition : must agree use least 2 effective contraceptive method throughout study 3 month follow date last dose study medication ; must negative serum pregnancy test obtain within 24 hour prior Day 1 . Males female partner childbearing potential must agree use least 2 effective contraceptive method throughout study avoid father child 6 month follow date last dose study medication . Be able provide write informed consent . Prior treatment azacitidine . Diagnosis malignant disease within previous 12 month ( exclude basal cell carcinoma complication ) . Diagnosis metastatic disease . Previous diagnosis hepatic tumor . Radiation therapy , chemotherapy , cytotoxic therapy , give treat condition MDS/AML administer within previous 12 month prior first day treatment ( Day 1 ) . Known suspected hypersensitivity azacitidine mannitol . Prior active disease , opinion Investigator , may interfere procedure evaluation conduct study . Serious medical illness likely limit survival equal 12 month screen likely prevent grant informed consent ( e.g. , history severe congestive heart failure , clinically unstable cardiac disease , pulmonary disease ) . Psychiatric illness would prevent grant informed consent ; Treatment erythropoietin myeloid growth factor ( granulocyte colonystimulating factor [ GCSF ] granulocytemacrophage colonystimulating factor [ GMCSF ] ) previous 21 day prior Day 1 . Treatment androgenic hormone previous 14 day prior Day 1 . Active viral infection know human immunodeficiency virus ( HIV ) viral hepatitis type B C. Treatment investigational drug within previous 30 day prior Day 1 , ongoing adverse event previous treatment investigational drug , regardless time period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>